Aptevo Therapeutics Inc.
APVO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for APVO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · APVO
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company developing novel immunotherapies based on its proprietary ADAPTIR and ADAPTIR-FLEX platforms, with a lead candidate in acute myeloid leukemia and a cash position of $9.8M as of June 30, 2026.
Key risk: Cash runway insufficient
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Aptevo Therapeutics Inc..
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company developing novel immunotherapies based on its proprietary ADAPTIR and ADAPTIR-FLEX platforms, with a lead candidate in acute myeloid leukemia and a cash position of $9.8M as of June 30, 2026.
- Aptevo is a clinical-stage, research and development biotechnology company focused on protein-based immunotherapies using its ADAPTIR and ADAPTIR-FLEX platforms [sec_mda · as of 2026-03-26].
- Cash and cash equivalents were $9.8 million as of June 30, 2026, with an accumulated deficit of $288.3 million [sec_mda · as of 2026-08-14].
- Net loss for the six months ended June 30, 2026 was $6.4 million (from latest reported financials as of 2026-06-30) [sec].
- The lead candidate mipletamig, in triplet combination therapy, continues to outperform standard of care ven/aza in unfit frontline acute myeloid leukemia patients, with a differentiated safety profile including no cytokine release syndrome [sec_mda · as of 2026-03-26].
- The company has expanded its CD3 portfolio with three new multispecific candidates leveraging its proprietary platform [sec_mda · as of 2026-03-26].
What works
- Mipletamig in triplet combination therapy continues to outperform standard of care ven/aza in unfit frontline AML patients, with a differentiated safety profile including no cytokine release syndrome [sec_mda · as of 2026-03-26].
- The ADAPTIR and ADAPTIR-FLEX platforms enable generation of monospecific, bispecific, and multi-specific protein immunotherapies, and can support combination therapy in emerging modalities including antibody-drug conjugates and radiopharmaceuticals [sec · filed 2026-08-21].
- The company has expanded its pipeline with three new multispecific candidates and introduced APVO455, a Nectin-4 x CD3 bispecific for solid tumors [sec_mda · as of 2026-03-26][sec_mda · as of 2025-08-11].
What to weigh
- Existing cash resources are not expected to be sufficient to fund operations for at least one year from the date the financial statements are issued [sec_mda · as of 2026-08-14].
- The company has an accumulated deficit of $288.3 million as of June 30, 2026 and will require substantial additional funding to complete clinical development of any product candidates [sec_mda · as of 2026-08-14][sec_mda · as of 2026-05-13].
- Net cash used in operating activities was $13.4 million for the six months ended June 30, 2026, and the company anticipates continuing significant operating losses for several years [sec_mda · as of 2026-08-14].
- The company may experience delays in partnering opportunities due to financial and macroeconomic impacts, including inflation and bank failures, which could affect future milestones from Medexus [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
Cash position and accumulated deficit as of June 30, 2026
“We had cash and cash equivalents of $ 9.8 million and an accumulated deficit of $288.3 million as of June 30, 2026.”
SEC MD&A · August 14, 2026
Cash runway concern
“our existing cash resources are not expected to be sufficient to fund operations for at least one year from the date the financial statements are issued.”
SEC MD&A · August 14, 2026
Platform capabilities
“We plan to generate additional monospecific, bispecific, and multi-specific protein immunotherapies for development, potentially with other collaborative partners, to exploit the potential of the ADAPTIR and ADAPTIR-FLEX platforms.”
SEC filings · August 21, 2026
Risks & what to watch (4)›
Key risks
- Cash runway insufficient — Existing cash not expected to fund operations for at least one year from issuance of financial statements [sec_mda · as of 2026-08-14].
- Need for substantial additional funding — Company requires substantial additional funds to complete clinical development and regulatory approval of product candidates [sec_mda · as of 2026-05-13].
- Significant accumulated deficit — Accumulated deficit of $288.3 million as of June 30, 2026, with continued operating losses expected [sec_mda · as of 2026-08-14].
- Partnering and macroeconomic risks — Potential delays in partnering opportunities and impacts on Medexus milestones due to macroeconomic factors [sec_mda · as of 2026-08-14].
What to watch
- Progress of mipletamig in frontline AML combination therapy and any new clinical data readouts [sec_mda · as of 2026-03-26].
- Advancement of the expanded CD3 portfolio, including APVO455 for solid tumors, into clinical development [sec_mda · as of 2026-03-26][sec_mda · as of 2025-08-11].
- Ability to secure additional funding or partnership agreements to extend cash runway beyond the next year [sec_mda · as of 2026-08-14].
- Achievement of milestone payments from Medexus related to IXINITY, with up to $5.8 million available by February 2035 [sec_mda · as of 2026-05-13].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Aptevo Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Aptevo Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
5.6 months
D/E 1.40 · 0% dilution
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
6
Total value held
$185K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 25,426 | $109K |
| geode capital management, llc | 13,337 | $57K |
| vanguard fiduciary trust co | 4,142 | $18K |
| osaic holdings, inc. | 360 | $2K |
| gsa capital partners llp | 19,638 | $84 |
| danske bank a/s | 1 | $4 |
Short Interest
as of May 20, 2026- % of float
- 7.8%
- Days to cover
- 2.8
- Shares short
- 92,205
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
APVO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Aptevo Therapeutics Inc.?
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company developing novel immunotherapies based on its proprietary ADAPTIR and ADAPTIR-FLEX platforms, with a lead candidate in acute myeloid leukemia and a cash position of $9.8M as of June 30, 2026.
What is Aptevo Therapeutics Inc.'s lead drug candidate?
Aptevo Therapeutics Inc.'s most advanced tracked candidate is mipletamig (Phase 1) for frontline acute myelogenous leukemia (AML).
Who is the CEO of Aptevo Therapeutics Inc.?
Mr. Jeffrey G. Lamothe CA is the chief executive officer of Aptevo Therapeutics Inc. (APVO).
Where is Aptevo Therapeutics Inc. headquartered?
Aptevo Therapeutics Inc. (APVO) is headquartered in Seattle, WA, United States.
What therapeutic areas does Aptevo Therapeutics Inc. focus on?
Aptevo Therapeutics Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.